

## Special Issue

# At the Interface of Genetics, Epigenetics and Metabolism in Cancer

### Message from the Guest Editors

This Special Issue will highlight a set of recent discoveries on metabolic and epigenetic reprogramming in cancer; in particular, it will focus on the “co-dependency” of genetics, epigenetics and metabolism, which contributes to the aggressive phenotypes of cancer cells, suggesting that these aberrations do not constitute a one-way street to sustaining cancer cell survival on their own, but that the mutual interdependency of genetics, epigenetics and metabolism could be a key to facilitating tumor progression, which will be, at the same time, an Achilles’ heel. These underscore the integration of genetic mutations with metabolic and epigenetic reprogramming in cancer, suggesting a new means to identifying patient subsets suitable for specific precision therapeutics.

---

### Guest Editors

Dr. Kenta Masui

Department of Integrative Neuroscience, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8523, Japan

Dr. Linlin Guo

Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN 46202, USA

---

### Deadline for manuscript submissions

closed (17 January 2023)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/83302](https://mdpi.com/si/83302)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)